CorEvitas Generalized Pustular Psoriasis (GPP) Drug Safety and Effectiveness Registry

Conditions

• Generalized Pustular Psoriasis

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Accepted

Study Details

Prospective, observational registry for subjects with GPP under the care of a dermatology investigator.Approximately 200 subjects and 75 clinical sites in North America will be recruited to participate with no defined upper limit for either target

Key Dates

Start date

Sep 19, 2023

Status verified

Aug 2025

Primary completion

Dec 31, 2099

Completion

Dec 31, 2099

Study Design

Enrollment

200 participants (estimated)

Arms

• Arm: Generalized Pustular Psoriasis (GPP)
  Pts presenting to enrolling sites across the North America are invited to enroll if eligible

Primary Outcome Measure

Primary Outcome Measure:GPP epidemiology and Presentation [ Time Frame: Through study completion, an average of 10 years ]

Central Contacts

• Cathy Cheney
  +1 508 408 5433
  [email protected]
• Jeffrey Greenberg, MD

Locations (1)

Find similar trials in Waltham, MA